Donate
Innovative and structuring nature
FHU CARE² (2025-2030) built on the network of FHU CARE (2020-2024) bring the expertise of:
- New intensive immunotherapy like CAR-T cells and Bispecific Tcell engagers (BiTEs): Camille Bigenwald (Hematology, Gustave Roussy) and Bernard Maillere (CEA, Cellular Immunology and Biotechnology lab)
- Cancer organoids: Fanny Jaulin (Gustave Roussy Invasion Collective, RHU Organomic, Orakl Oncology) and Charles Baroud (Institut Pasteur, Laboratoire d’Hydrodynamique (LadHyX) and Milena Hasan (Institut Pasteur)
- Artificial intelligence: Paul-Henry Cournède, Wassila Ouerdane (CentraleSupélec Mics Lab), Gaël Varoquaux , Judith Abecassis (Inria Saclay, Soda research team) and Anna Niarakis (Computational Systems Biology at the University of Toulouse III-Paul Sabatier)
All the partners are united by a geographical proximity in the south of Paris and are all in the Paris–Saclay University and hospitals ecosystem. This agile network allows for frequent face to face meetings and discussions that effectively allow the project to gain momentum.
Axis 1 : New Tools
- To create immuno-organoids from tissue of patients with AID on the model of cancer organoids
- Use of EDS and SNDS for studying the risk of different cancers in different AID with different treatments
Axis 2 : New Mechanisms
- To study the impact on cancer immunosurveillance of JAK inhibitors and other anti-inflammatory biologic drugs
- To decipher the transition between autoimmunity and lymphoma in the model of Sjögren disease
Axis 3 : New Treatments
- RCT of immunosuppressive biologic drugs in IrAEs post ICI
- RCT with association of immunosuppressive biologic drugs and immune check-point in cancer
- Intensive immunotherapy platform AID (CART-T cells developed locally in a close device, CAAR-T cells,) T-cell engagers bi-specific Ab,
Axis 4 : New Education
- Development of the MOOC on relations between autoimmunity and cancer
- New course on intensive immune therapies to treat cancer and auto-immune diseases
FHU CARE² allows to structure interactions between these teams, in order to boost university and hospital relations and improves:
- The innovation in research to build new models to develop and test new drugs inspired from cancer in autoimmune diseases and autoimmune diseases in cancer.
- The clinical research to encourage and support all clinical trials in autoimmune diseases and cancers taking advantage of the expertise in each field to benefit the other.
- The quality of teaching: creation of dedicated courses on intensive immunotherapy in cancer and autoimmune diseases to favor interactions for MD, PhD, nurses and health professionals, but also engineers and people from industry from all fields.
Standing on the foundation build with FHU CARE and FHU CARE² is more focused on innovative therapeutics and is able to effectively transform the life of patients with autoimmune diseases and cancer with rapidly available treatments.
Attractiveness in FHU CARE²:
- Patients: We are a reference center allowing to recruit patients with common or rare severe autoimmune diseases. Institut Gustave Roussy has one of the largest phase 1 cancer trial centers in Europe with a large recruitment capacity.
- Researchers: FHU CARE² can rely on partners in a fertile environment of medical, pharmaceutical and engineering schools like Centrale Supelec and ENS Paris Saclay. FHU CARE² attracts talents from these institutions by organizing local events in these schools.
- Health care professionals: We already have a national level of experts from all medical fields including rheumatologists, hematologists, internal medicine specialists, CRI, and reference centers, etc.) called Club Immune mediated inflammatory diseases (IMID) Intensive Immunotherapy (C3i [Linked In]) which is part of a Rare disease network. This allows to have national and international visibility.
FHU CARE² has also a strong Partnership (non-exhaustive list) with non-hospital-based healthcare providers and pharmaceutical companies involved in autoimmune diseases and in cancer
- Fresenius Kabi which financially supports the CITAR trial (Axis 3 task 1) for the trial drug and the study costs of the French centers.
- A partnership with Inria (especially the research team SODA based in Saclay) and Centrale Supélec Mics Lab led by Paul-Henry Cournède and Wassila Ouerdane.
- A strong partnership with Foundation Arthritis which privately funds research in rheumatology and have participated in the creation of special funding call for on the relationship between cancer and autoimmune diseases.
- Amgen which has the first approved CD19xCD3 BiTE (Blinatumomab) and an anti-CD19 used in neuromyelitis optica (Inebilizumab).
Finally, FHU CARE² has a strong collaboration with INCA, ANSES, the Arthritis and the FOREUM Foundations and a major area of interest (DIM) on immunotherapy, autoimmunity and cancer (DIM ITAC) coordinated by Caroline Robert at Gustave Roussy Institute & Xavier Mariette at AP-HP.This is a major achievement enabling to push the field to the forefront of the biggest French region.